Meeting
2018 ASCO Annual Meeting
The natural course of hypermutator gliomas.
Authors
Carlos Kamiya-Matsuoka
The University of Texas MD Anderson Cancer Center, Department of Neuro-Oncology, Houston, TX
Carlos Kamiya-Matsuoka , Nicholas Robert Metrus , Kenna Rael Shaw , Marta Penas-Prado , Shiao-Pei S. Weathers , Monica Elena Loghin , Kristin Alfaro-Munoz , Ying Yuan , Barbara Jane O'Brien , Rebecca A. Harrison , W. K. Alfred Yung , Funda Meric-Bernstam , John Frederick De Groot
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Citation
J Clin Oncol 36, 2018 (suppl; abstr 2014)
DOI
10.1200/JCO.2018.36.15_suppl.2014
Abstract #
2014
Poster Bd #
172
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Retrospective review for outcomes of IDH mutant, 1p/19q co-deleted gliomas based on initial treatment.
First Author: Christopher Ray Trevino
Poster
2021 ASCO Annual Meeting
Malignant glioma subset from Actuate 1801: A phase 1/2 study of 9-ING-41, a glycogen synthase kinase 3 beta (GSK-3β) inhibitor, as a single agent and combined with chemotherapy, in patients with refractory hematologic malignancies or solid tumors.
First Author: Yazmin Odia
Poster
2019 ASCO Annual Meeting
A phase Ib trial of CB-839 (telaglenastat) in combination with radiation therapy and temozolomide in patients with IDH-mutated diffuse astrocytoma and anaplastic astrocytoma (NCT03528642).
First Author: Sani Haider Kizilbash
First Author: Marc C. Chamberlain